Literature DB >> 10446738

Care of depressed patients with anxiety symptoms.

D J Nutt1.   

Abstract

Anxiety frequently coexists with depression, either as a comorbid anxiety disorder or as anxiety symptoms accompanying a primary depressive disorder. Effective therapy for the treatment of depressive illness must include a consideration of anxiety symptoms, since anxiety has been estimated to be present in up to 96% of patients with depressive illness. Available data also indicate that depressed patients with significant anxiety may be at greater risk for suicide. Of particular clinical importance are symptoms of somatic anxiety: they are present in up to 86% of depressed patients, and the failure to treat them effectively can diminish the ability of a patient to function. Since the overall prognosis for recovery from a major depressive episode is less than optimal in patients with significant anxiety, treatments that can provide an effective and early relief of both depressive and anxiety symptoms are of paramount importance. Drugs with serotonin reuptake inhibition (such as selective serotonin reuptake inhibitors [SSRIs] or serotonin-norepinephrine reuptake inhibitors [SNRIs]) may produce transient increases in anxiety symptomatology presenting as jitteriness, agitation, insomnia, and gastrointestinal symptoms when treatment is initiated. Mirtazapine has intrinsic receptor-blocking properties (in particular, serotonin-2 [5-HT2] receptor blockade) that can be linked to an early relief of anxiety symptoms during the treatment. The available data show that mirtazapine is superior to placebo in depressed patients with high baseline anxiety and/or agitation. Furthermore, mirtazapine was statistically significantly superior to both citalopram and paroxetine in alleviating anxiety symptoms early in treatment as assessed by changes from baseline on the Hamilton Rating Scale for Anxiety or the Hamilton Rating Scale for Depression anxiety/somatization factor, respectively. Mirtazapine provides early and effective relief of both depressive and anxiety symptoms, reducing the need for polypharmacy. These therapeutic actions of mirtazapine persist throughout the course of treatment.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10446738

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  7 in total

1.  Panic Attacks During Escalation of Mirtazapine.

Authors:  Timothy R. Berigan
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2003-04

Review 2.  Escitalopram : a review of its use in the management of major depressive and anxiety disorders.

Authors:  John Waugh; Karen L Goa
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

3.  Experience of the use of velaxin (venlafaxine) in anxious depression.

Authors:  N A Il'ina
Journal:  Neurosci Behav Physiol       Date:  2009-03

4.  Psychometric properties of the Danish Hospital Anxiety and Depression Scale in patients with cardiac disease: results from the DenHeart survey.

Authors:  Anne Vinggaard Christensen; Jane K Dixon; Knud Juel; Ola Ekholm; Trine Bernholdt Rasmussen; Britt Borregaard; Rikke Elmose Mols; Lars Thrysøe; Charlotte Brun Thorup; Selina Kikkenborg Berg
Journal:  Health Qual Life Outcomes       Date:  2020-01-07       Impact factor: 3.186

5.  Scared to Trust? - Predicting Trust in Highly Automated Driving by Depressiveness, Negative Self-Evaluations and State Anxiety.

Authors:  Johannes Kraus; David Scholz; Eva-Maria Messner; Matthias Messner; Martin Baumann
Journal:  Front Psychol       Date:  2020-01-23

Review 6.  The relevance of 'mixed anxiety and depression' as a diagnostic category in clinical practice.

Authors:  Hans-Jürgen Möller; Borwin Bandelow; Hans-Peter Volz; Utako Birgit Barnikol; Erich Seifritz; Siegfried Kasper
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-03-22       Impact factor: 5.270

7.  Does anxiety moderate the effectiveness of mirtazapine in patients with treatment-resistant depression? A secondary analysis of the MIR trial.

Authors:  Raphael Rifkin-Zybutz; Stephanie MacNeill; Simon Jc Davies; Christopher Dickens; John Campbell; Ian M Anderson; Carolyn A Chew-Graham; Tim J Peters; Glyn Lewis; Nicola Wiles; David Kessler
Journal:  J Psychopharmacol       Date:  2020-11-04       Impact factor: 4.153

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.